Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2024 Financial Results on March 27, 2025
Rhea-AI Summary
Acumen Pharmaceuticals (NASDAQ: ABOS), a clinical-stage biopharmaceutical company focused on developing a novel treatment for Alzheimer's disease targeting toxic soluble amyloid beta oligomers, has scheduled its fourth quarter and year-end 2024 financial results announcement for March 27, 2025.
The company will host a conference call and live audio webcast at 8:00 a.m. ET to discuss business updates and financial performance. Interested participants must pre-register at least one day in advance to receive dial-in numbers and PIN. The webcast will remain accessible for a minimum of 30 days through the Investors section of Acumen's website.
Positive
- None.
Negative
- None.
News Market Reaction
On the day this news was published, ABOS gained 1.69%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
NEWTON, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, today announced that the Company will report fourth quarter and year-end 2024 financial results on Thursday, March 27, 2025. The Company will host a conference call and live audio webcast at 8:00 a.m. ET to provide a business and financial update.
To participate in the live conference call, please register using this link. After registration, you will be informed of the dial-in numbers including PIN. Please register at least one day in advance.
The webcast audio will be available via this link.
An archived version of the webcast will be available for at least 30 days in the Investors section of the Company's website at www.acumenpharm.com.
About Acumen Pharmaceuticals, Inc.
Acumen Pharmaceuticals is a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease (AD). Acumen’s scientific founders pioneered research on AβOs, which a growing body of evidence indicates are early and persistent triggers of Alzheimer’s disease pathology. Acumen is currently focused on advancing its investigational product candidate, sabirnetug (ACU193), a humanized monoclonal antibody that selectively targets toxic soluble AβOs, in its ongoing Phase 2 clinical trial ALTITUDE-AD (NCT06335173) in early symptomatic Alzheimer’s disease patients, following positive results in its Phase 1 trial INTERCEPT-AD. The company is headquartered in Newton, Mass. For more information, visit www.acumenpharm.com.
Investors:
Alex Braun
abraun@acumenpharm.com
Media:
AcumenPR@westwicke.com
FAQ
When will Acumen Pharmaceuticals (ABOS) release its Q4 and full-year 2024 earnings?
How can investors join ABOS's Q4 2024 earnings call?
Where can investors access ABOS's Q4 2024 earnings webcast replay?
What is the main therapeutic focus of Acumen Pharmaceuticals (ABOS)?
